Literature DB >> 12884367

Functional evaluation of novel single nucleotide polymorphisms and haplotypes in the promoter regions of CYP1B1 and CYP1A1 genes.

Weiguo Han1, Brian T Pentecost, Simon D Spivack.   

Abstract

Interindividual variation in the expression of the carcinogen- and estrogen-metabolizing enzymes cytochrome P4501B1 and 1A1 (CYP1B1 and CYP1A1) has been detected in human lung. To search for polymorphisms with functional consequences for CYP1B1 and CYP1A1 gene expression, we examined 1.5 kb of the promoter region of each gene. Genomic DNA from 21 Caucasian individuals was amplified by polymerase chain reaction (PCR) for direct cycle sequencing. Eight single nucleotide polymorphisms (SNPs) for CYP1B1 and 13 SNPs for CYP1A1 were found. The majority of polymorphisms occurred as multiSNP combinations for individual subjects. The wild-type sequences were cloned into a luciferase reporter construct. The most frequent polymorphisms were then recreated by iterative site-directed mutagenesis, replicating single polymorphisms and multiSNP combinations. These wild-type and variant constructs were functionally evaluated in transient transfection experiments employing exposures to either the index polycyclic aromatic hydrocarbon (PAH) inducer benzo[a]pyrene (B[a]P), a composite mixture of cigarette smoke extract (CSE), or the repressor chemopreventive agent trans-3,4,5-trihydroxystilbene (reseveratrol). Results indicated that all wild-type and variant constructs responded in qualitatively concordant fashion to the inducers and to the repressor. The CYP1B1 haplotypes and the majority of CYP1A1 haplotypes were shown to have no functional consequence, as compared to those of the wild-type promoter sequences. Two constructs of composite polymorphisms of CYP1A1 appeared to result in a statistically significant increase in basal promoter activity (1.38- and 1.50-fold, respectively), but the degree of functional impact was judged unlikely to be biologically important in vivo. We conclude that the observed promoter region polymorphisms in these genes are common, but are of unclear functional consequence. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12884367     DOI: 10.1002/mc.10132

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  5 in total

1.  Estrogen receptor alpha increases basal and cigarette smoke extract-induced expression of CYP1A1 and CYP1B1, but not GSTP1, in normal human bronchial epithelial cells.

Authors:  W Han; B T Pentecost; R L Pietropaolo; M J Fasco; S D Spivack
Journal:  Mol Carcinog       Date:  2005-11       Impact factor: 4.784

2.  Effect of tumor necrosis factor-alpha on estrogen metabolism and endometrial cells: potential physiological and pathological relevance.

Authors:  Salama A Salama; Marwa W Kamel; Concepcion R Diaz-Arrastia; Xia Xu; Timothy D Veenstra; Sana Salih; Shaleen K Botting; Raj Kumar
Journal:  J Clin Endocrinol Metab       Date:  2008-10-28       Impact factor: 5.958

3.  CYP1B1 polymorphisms and k-ras mutations in patients with pancreatic ductal adenocarcinoma.

Authors:  Marta Crous-Bou; Immaculata De Vivo; Miquel Porta; José A Pumarega; Tomàs López; Joan Alguacil; Eva Morales; Núria Malats; Juli Rifà; David J Hunter; Francisco X Real
Journal:  Dig Dis Sci       Date:  2008-03-18       Impact factor: 3.199

4.  Identification of novel potential genetic predictors of urothelial bladder carcinoma susceptibility in Pakistani population.

Authors:  Syeda Hafiza Benish Ali; Kashif Sardar Bangash; Abdur Rauf; Muhammad Younis; Khursheed Anwar; Raja Khurram; Muhammad Athar Khawaja; Maleeha Azam; Abid Ali Qureshi; Saeed Akhter; Lambertus A Kiemeney; Raheel Qamar
Journal:  Fam Cancer       Date:  2017-10       Impact factor: 2.375

5.  The effect of dietary zinc--and polyphenols intake on DMBA-induced mammary tumorigenesis in rats.

Authors:  Barbara Bobrowska-Korczak; Dorota Skrajnowska; Andrzej Tokarz
Journal:  J Biomed Sci       Date:  2012-04-16       Impact factor: 8.410

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.